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Sensitivity and specificity 
Diagnosis 
QuantiFERON 
s u m m a r y 
Background: There is an urgent need for new tools for the diagnosis of TB. We evaluated the usefulness 
recently described host biomarkers in supernatants from the newest generation of the QuantiFERON test 
(QuantiFERON Plus) as tools for the diagnosis of active TB. 
Methods: We recruited individuals presenting at primary health care clinics in Cape Town, South Africa 
with symptoms requiring investigation for TB disease, prior to the establishment of a clinical diagnosis. 
Participants were later classified as TB or other respiratory diseases (ORD) based on the results of clinical 
and laboratory tests. Using a multiplex platform, we evaluated the concentrations of 37 host biomarkers 
in QuantiFERON Plus supernatants from study participants as tools for the diagnosis of TB. 
Results: Out of 120 study participants, 35(29.2%) were diagnosed with active TB, 69(57.5%) with ORD 
whereas 16(13.3%) were excluded. 14(11.6%) of the study participants were HIV infected. Although individ- 
ual host markers showed potential as diagnostic candidates, the main finding of the study was the identi- 
fication of a six-marker biosignature in unstimulated supernatants (Apo-ACIII, CXCL1, CXCL9, CCL8, CCL-1, 
CD56) which diagnosed TB with sensitivity and specificity of 73.9%(95% CI; 51.6–87.8) and 87.6%(95% CI; 
77.2–94.5), respectively, after leave-one-out cross validation. Combinations between TB-antigen specific 
biomarkers also showed potential (sensitivity of 77.3% and specificity of 69.2%, respectively), with multi- 
ple biomarkers being significantly different between TB patients, Quantiferon Plus Positive and Quantif- 
eron Plus negative individuals with ORD, regardless of HIV status. 
Conclusions: Biomarkers detected in QuantiFERON Plus supernatants may contribute to adjunctive diag- 
nosis of TB. 
© 2019 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 












i  Introduction 
An estimated 10.4 million people were reported to have fallen
ill with tuberculosis (TB), and another 1.6 million died of the dis-
ease in 2017. 1 The currently existing diagnostic tests have several
widely publicised limitations 2,3 including poor sensitivity (smear
microscopy), 4 long turnaround times and high costs (culture). 5 The∗ Corresponding author. 
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( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) eneXpert MTB/RIF test (Cepheid, Sunnyvale, CA, USA), is relatively
apid and detects resistance to rifampicin, but is also expensive,
ith low specificity in recurrent TB. 6 These tests are not very suit-
ble for people with difficulty in providing good quality sputum
amples such as children and those with extrapulmonary TB. 7 Im-
unological approaches have been shown to be potentially useful
n these forms of TB, and may be easily converted into point-of-
are screening tests. 5–7 
The tuberculin skin test (TST) and interferon gamma (IFN- γ ) re-
ease assays (IGRAs) remain the only approved immunodiagnostic
ests for the management of TB. As these tests cannot distinguishion Association. This is an open access article under the CC BY-NC-ND license. 



























































































































etween latently infected individuals and those with active TB, 8,9 
hey are not recommended for diagnosis of active TB in high bur-
en settings, due to the high prevalence of LTBI. 10 Many investi-
ators have evaluated alternative antigens other than those used
n IGRAs (ESAT-6 and CFP-10) 11–13 and alternative host biomark-
rs other than IFN- γ 8,12 as biomarkers for active TB. Investigations
one in QuantiFERON TB Gold (QFT) In Tube culture supernatants
n particular, identified promising biosignatures for the diagnosis
f active pulmonary TB in both adults 14,3 , 16 and children. 15,17 The
FT In Tube test which contained ESAT-6, CFP-10 and TB7.7 pep-
ides has been replaced by the recently introduced QFT Plus, which
nly contains CFP-10 and ESAT-6 peptides, but includes a second
B antigen tube. 18 The first TB antigen tube (TB1) contains long
eptides that reportedly elicit CD4 T cell immune responses and
he TB2 tube contains both short and long peptides which elicit
D4 and CD8 T cell immune responses. 19 
According to the manufacturer (Qiagen, Germany), the QFT
lus reportedly has high sensitivity ( > 95%) and boasts the highest
pecificity of any test for the diagnosis of Mycobacterium tubercu-
osis (M. tb) infection. 18 Given that host immunological biomarkers
etected in QFT In Tube supernatants were shown to have poten-
ial as diagnostic biomarkers for active TB in several studies, re-
iewed in, 20 it is not known whether the findings from these stud-
es can be replicated in supernatants from the QFT Plus system.
iven the reportedly higher sensitivity and specificity of the QFT
lus, 18 the use of alternative biomarkers detectable in QFT Plus su-
ernatants may be useful in the diagnosis of active TB, as shown in
 recent report with IP-10. 21 Biosignatures based on such antigen-
pecific responses may enhance the specificity of host biomarker-
ased tests. In the present study, we evaluated the utility of mul-
iple host immunological biomarkers that have previously been
hown to possess diagnostic potential for active TB in QFT Plus
upernatants. We also included biomarkers that showed potential
n recent studies done on serum or plasma specimens 27 , 28 and
ther recently identified host biomarkers, as diagnostic candidates
or active TB in QFT Plus supernatants from individuals suspected
f having TB disease in a high TB endemic setting. 
aterials and methods 
We prospectively recruited individuals presenting at primary
ealth care clinics in Cape Town, South Africa with symptoms re-
uiring investigation for TB disease, prior to the diagnosis of TB
r other diseases as part of a larger ongoing multisite project
ScreenTB; www.screen-tb.eu ). Participants were enrolled between
ovember 2016 and October 2017 ( Fig. 1 ). Participants were eli-
ible for inclusion in the study if they self-reported at the clinic
ith symptoms or signs suggestive of TB, namely coughing for ≥2
eeks in addition to at least one other symptom or sign including
ever, weight loss, haemoptysis, malaise, night sweats, chest pain
r loss of appetite. Other eligibility criteria included age between
8 and 70 years, and willingness to give written informed consent
nd undergo HIV testing. Participants were excluded if they had
ot been living in the study community for up to 3 months, had
o permanent address, if they were pregnant or breast feeding, had
B < 9 g/l, were on TB treatment or had received anti-TB treatment
n the previous 90 days, if they were HIV positive and on isoni-
zid prophylaxis, and if they had been treated with quinolone or
minoglycoside antibiotics in the previous 60 days. The study was
pproved by the Health Research Ethics Committee of the Univer-
ity of Stellenbosch. 
ollection of specimens and diagnostic tests 
Whole blood was collected by venepuncture, directly into QFT
lus tubes (1 mL to each of the nil, TB1, TB2 and mitogen tubes) asecommended by the manufacturer (Qiagen, Germany). Tubes were
ransported at ambient conditions to the laboratory after which
hey were incubated for 18 to 20 h at 37 °C, in a 5% CO 2 incu-
ator. Tubes were then centrifuged at 30 0 0 x g for 15 min as
ecommended by the manufacturer and supernatants harvested,
liquoted and frozen at −80 °C until use. Sputum samples collected
rom all study participants were tested for M. tb using the GeneX-
ert, followed by culture using the MGIT method (BD Biosciences).
pecimens which showed growth of microorganisms were further
xamined for acid fast bacilli using the Ziehl–Neelsen method, fol-
owed by and Capilia TB testing (Tauns, Japan) to confirm the iso-
ation of organisms of the M.tb complex before being classified as
ositive cultures. 
eference standard for classification of study participants 
Participants were classified as either definite TB, probable TB or
ther respiratory diseases (ORD) using a composite reference stan-
ard combination of clinical, laboratory and radiological findings
s previously described. 3,22 As in previous studies, 3,23,24 individuals
ith ORD had a variety of other diagnoses which included upper
nd lower respiratory tract infections and acute exacerbations of
hronic obstructive pulmonary diseases or asthma. However, more
xtensive investigations including bacterial and viral cultures were
ot done to confirm all the ORDs as it is not standard practice in
he primary health care clinics where study participants were re-
ruited. 
uantiFERON-TB gold plus ELISA 
IFN- γ concentrations in QFT Plus supernatants were deter-
ined using standard QFT Plus ELISA kits. All experiments were
one and data analysed and interpreted using the analysis soft-
are provided by the manufacture (Qiagen). ELISA results were
nly used for determination of the M. tb infection status of study
articipants and not for patient management. 
uminex multiplex immunoassay 
The concentrations of 37 host biomarkers that were identified
s TB diagnostic candidates after literature searches 14,23,38 were
valuated in the nil, TB1 and TB2 antigen stimulated culture su-
ernatants from all study participants. These included apolipopro-
ein (Apo) A-1, Apo-CIII, complement factor H (CFH), IFN- α2,
acrophage inflammatory protein 1 alpha (MIP-1 α/CCL3), inter-
eukin (IL) −4, IL-6, in reagent kits purchased form Merck Mil-
ipore, Billerica, MA , USA , and neural cell adhesion molecule-
 (NCAM-1/CD56), transforming growth factor (TGF)- α, IFN-
, monokine induced by IFN- γ (CXCL9/MIG), p-selectin, epi-
ermal growth factor (EGF), tumour necrosis factor superfam-
ly member 14 (TNFSF14/LIGHT), monocyte chemotactic protein
MCP-1/CCL2), MCP-2(CCL8), MIP-1 β (CCL4), vascular endothelial
rowth factor-A (VEGF-A), von Willebrand factor-cleaving protease
ADAMTS13), CD40 ligand (CD40L), interferon inducible T-cell al-
ha chemoattractant (CXCL11/ITAC-1), IFN- γ inducible protein-10
IP-10/CXCL10), tumour necrosis factor (TNF)- α, Fas, IL-1 β , granu-
ocyte monocyte colony stimulating factor (GM-CSF), IL-8(CXCL8),
L-3, IL-15, IL-13, IL-2, IL-33, IL-1 α, IL-10, IL-1 receptor agonist (IL-
ra), and IL-22, which were in reagent kits purchased from R&D
ystems Inc. (Biotechne, Minneapolis, MN, USA). All experiments
ere performed in a blinded manner, on the Bio Plex platform
Bio-Rad Laboratories, Hercules, USA) with the Bio-Plex Manager
oftware (version 6.1) used for bead acquisition and analysis of
edian fluorescent intensity. The values of analytes in the respec-
ive quality control reagents evaluated on all plates, were within
heir expected reference ranges. 
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Fig. 1. STARD flow diagram showing the study design and classification of participants. ∗These study participants were excluded either because they had culture contam- 
ination in addition to having negative sputum smear results ( n = 8) or because of loss to follow-up during TB workup ( n = 8). TB = pulmonary tuberculosis, ORD = other 





























C linical and demographic characteristics of study participants with a tu- 
berculosis or other respiratory disease diagnosis. Data for the 16 excluded 
study participants not shown. 
All TB disease ORD 
No. of patients 104 35 (29.1%) 69 (70.8%) 
Female’s n (%) 64 (53.3%) 10 (28.5%) 46 (66.6%) 
Age mean ± SD 40.1 ± 12.6 34.8 ± 12.1 41.9 ± 12.6 
HIV positive n (%) 9 (8.7%) 7 (20.0%) 2 (3%) 
QFT plus Positive n (%) 87 (72.5%) 27 (77.1) 49 (71%) 
QFT plus Negative n (%) 32 (26.7%) 8 (22.8) 20 (28.9) 
Indeterminate n (%) 1 (1%) 1 (2.9%) 0 (0%) 
We intended to classify all study participants as definite TB, Probable 
TB, possible TB or ORD using the pre-established diagnostic algorithm 
described in (26). However, all individuals classified as TB in this study 
were culture and GeneXpert positive (definite TB). Participants classified 
as ORD were culture negative, smear negative and had no TB suggestive 
chest X rays. Furthermore, none of these participants was treated for TB 
by the TB control program. Abbreviations: TB = Tuberculosis, ORD = other 
respiratory disease, SD = standard deviation, HIV = Human immunodefi- 
















n  Statistical analysis 
The Mann-Whitney U test was used for assessing differences in
the concentrations of individual host biomarkers between any two
groups e.g., TB vs. ORD. The diagnostic accuracy of individual mark-
ers was evaluated by receiver operator characteristics (ROC) curve
analysis. Cut-off values and associated sensitivity and specificity
were determined using the Youden’s Index. The General discrim-
inant analysis (GDA) procedure was used to assess the predictive
abilities of combinations between different host biomarkers. Pre-
diction accuracy was ascertained by leave-one-out cross validation.
P -values ≤ 0.05 were considered significant. Data were analysed
using Graph Pad Prism version 7.04 (San Diego, CA, USA) and Sta-
tistica (TIBCO Software Inc., CA, USA). 
Results 
A total of 120 study participants were enrolled into the cur-
rent study, 14(11.6%) of whom were HIV infected. 16 (13.3%) of the
study participants were excluded for reasons explained in Fig. 1 .
The mean age of the remaining 104 participants was 40.1 ± 12.6
years and 40(38.5%) were males. Using the manufacturer’s recom-
mended cut-off value ( ≥0.35IU/mL), 87(72.5%) of all study par-
ticipants were QFT Plus positive. We intended to employ our
pre-established composite reference standard comprising of clinical
information, laboratory (smear, GeneXpert and culture) and imag-
ing findings to classify study participants as definite TB, probable
TB, possible TB or ORD as reported in previous studies. 3,14 How-
ever, all participants that were finally diagnosed with TB in the
present study ( n = 35; 29.2%) were culture and GeneXpert positive,
with 24 (68.6%) being smear positive ( Table 1 ). 
Utility of individual biomarkers in the diagnosis of TB 
We evaluated the differences in the concentrations of biomark-
ers detected in culture supernatants after stimulation with the
TB1 and TB2 antigens, and the nil (unstimulated) responses sep-rately to assess the contribution of unstimulated biomarkers in
he diagnosis of active TB as previously reported. 11,14 TB1 and
B2 responses were corrected for background by subtraction of
he unstimulated values prior to analysis. We first evaluated the
orrelation between IFN- γ values determined using the QFT Plus
LISA (IU/mL) and what was detected using the Luminex platform
pg/mL). As observed in previous studies, 14,24 there was a signifi-
ant positive correlation between IFN- γ values detected by ELISA
nd Luminex in both the nil ( r = 0.2164), and the TB1( r = 0.4278,
nd TB2 ( r = 0.526) stimulated values, at p < 0.05). 
Host markers detected in unstimulated (nil) supernatants: when
he concentrations of host markers detected in the QFT Plus nil
upernatants from TB patients were compared to responses ob-
ained in individuals with other respiratory diseases (ORD) with
he Mann Whitney U test irrespective of HIV infection status, sig-
ificant differences ( P ≤ 0.05) were observed for the concentrations
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Table 2 
Median concentrations of host markers (Inter-quartile ranges in parenthesis) detected in unstimulated (nil) culture supernatants and accuracies in the diagnosis of TB disease 
( n = 35) and other respiratory diseases ( n = 69). Only biomarkers that showed significant differences ( p ≤ 0.05) between groups with the Mann Witney U test are shown. 
AUC = Area under the ROC curve, CI = Confidence interval. Cut-off values were selected based on the Youden’s Index. All concentrations are in pg/mL with the exception of 
Apo-A1and Apo-CIII (ng/mL). 
Marker ORD ( n = 69) (IQR) TB disease ( n = 35) (IQR) P value AUC (95%CI) Cut-off value Sensitivity (95% CI) Specificity (95% CI) 
ITAC-1 310 (238–450) 561 (381–753) 0,0001 0.77 (0.67–0.80) > 381.70 78 (56–92) 62 (48–73) 
IL-3 35 (24–43) 44 (38–48) 0,0008 0.75 (0.63–0.86) > 40.85 76 (53–92) 65 (52–76) 
I-309 11 (8–13) 18 (10–26) 0,0001 0.73 (0.62–0.84) > 11.09 71 (54–85) 55(43–67) 
MIG 890 (772–1095) 1133 (873–1645) 0,0014 0.73 (0.60–0.85) > 940.30 70 (47–87) 57 (44–69) 
Apo- CIII 281,738 (169,471–838,212) 122,386 (80,337–295,193) 0,0013 0.69 (0.59–80) < 203,602 71 (54–85) 65 (53–76) 
IL-1 α 43 (23–67) 62 (47–78) 0,0066 0.69 (0.57–0.81) > 50.87 74 (52–90) 62 (49–73) 
IL-33 20 (3–45) 41 (29–55) 0,0065 0.69 (0.58–0.81) > 28.20 78 (59–92) 58 (45–71) 
Apo-A1 710,225 (394,468–1,525,800 346,446 (190,034–653,295 0,0032 0.68 (0.57–0.59) < 536,691 73 (54–87) 65 (53–76) 
ADAMTS13 1,418,300 (1,061,200–1,762,700) 71,289 (71,289–1,496,500) 0,0137 0.67 (0.54–0.81) < 203,602 67 (47–86) 64 (57–80) 
IL-2 1180 (563–1552) 1555 (1275–1707) 0,0145 0.67 (0.55–0.76) > 1363 70 (47–87) 65 (50–75) 
NCAM-1 126,811 (19,041–154,833) 100,864 (75,770–132,990) 0,0047 0.67 (0.56–0.78) < 124,132 72 (53–86) 54 (41–66) 
GM-CSF 37 (23–56) 62 (25–94) 0,0134 0.65 (0.53–0.77) > 40.81 71 (54–85) 55 (43–65) 
IL-22 28 (15–41) 36 (31–44) 0,0389 0.65 (0.53–0.77) > 29.12 90 (69–99) 57 (44–96) 
TGF- α 23 (18–34) 31 (19–51) 0,0213 0.64 (0.53–0.76) > 28.32 64 (45–80) 65 (53–76) 
Table 3 
Median concentrations of host markers (Inter-quartile ranges in parenthesis) detected in TB1 antigen stimulated culture supernatants and accuracies in the diagnosis of TB 
disease. Only biomarkers that showed significant differences ( p ≤ 0.05) or trends (0.05 < 9 ≤ 0.1) between groups with the Mann Witney U test are shown. AUC = Area under 
the ROC curve, CI = Confidence interval. Cut-off values were selected based on the Youden’s Index. All concentrations are in pg/mL. 
Markers ORD( n = 69) (IQR) TB( n = 35) (IQR) P value AUC (95% CI) Cut-off value Sensitivity (95% CI) Specificity (95% CI) 
P-Selection 0.197 ( −0.3806–0.6405) −0.4173 ( −1.447–0.4049) 0.0277 0.66 (0.52–0.80) 0.04329 68 (45–86) 60 (47–72) 
MIP-1 α −0.1339 ( −0.2646–0.3281) 0.2562 ( −0.537–0.04445) 0.0816 0.64 (0.53–0.76) −0.1554 70 (51–84) 55 (43–67) 
IL-2 −0.137 ( −0.2132–0.7377) −0.088795 ( −0.0341-( −0.1149) 0.0491 0.64 (0.52–0.74) 0.4564 68 (45–86) 60 (44–69) 
LIGHT −0.0934 ( −0.7485–0.7281) −0.4049 ( −0.792–0.1191) 0.0794 0.63 (0.50–0.73) −0.2076 71 (48–89) 52 (40–65) 
IL-13 −0.0892 (0.2827.518) −0.2463 ( −0.518–0.0051) 0.0484 0.62 (0.51–0.57) −0.128 70 (0.51–0.84) 54 (41–66) 
GM-CSF 0.2213 ( −0,3758–0.2015) −0.2611 ( −0.7483–0402) 0.05834 0,62 (0.51–0,73) −0.02804 66 (48–81) 62 (50–74) 
IL-10 0.2727 ( −0.2287–0.7325) 0.00814 ( −0.4544–0.2281) 0.0548 0.62 (0.51–0.73) 0.2201 73 (55–88) 52 (40–64) 
Values shown were background corrected by subtraction of the unstimulated from the antigen-stimulated concentration for each study participant. A negative value before 































































(  f 14 of the 37 markers evaluated. The median concentrations
f ITAC-1, IL-2, IL-3, I-309, MIG, ADAMTS13, IL-1 α, GM-CSF, IL-
3, IL-22, and TGF- α were significantly higher in the TB patients
hereas, the concentrations of Apo-A1, Apo-CIII and NCAM-1were
ignificantly higher in the ORD group ( Table 2 ). When the diag-
ostic accuracy of these proteins were assessed using ROC curve
nalysis, the areas under the ROC curves (AUCs) were ≥0.65 for
3 of these analytes, with ITAC-1, IL-3, I-309, and MIG being
he most accurate individual markers (AUCs > 0.70). When only
he HIV uninfected individuals were considered, only the same
4 host markers showed significant differences between the two
roups. 
Host markers detected in TB1 antigen-specific supernatants : when
he TB1 antigen-specific (TB1 antigen-minus-nil) host markers,
ere compared between the TB and ORD groups, the median lev-
ls of seven host markers were significantly different between the
wo groups. The concentrations of MIP-1 α and IL-2 were signifi-
antly higher in TB patients whereas those of p-selectin, IL-13, IL-
0, LIGHT, and GM-CSF were higher in ORD group ( Table 3 ). These
even host markers diagnosed TB with AUC ≥0.60 after ROC curve
nalysis, with MIP-1 α, p-selectin, and IL-2 being the most accurate
ndividual markers. 
Host markers detected in TB2 antigen-specific supernatants: when
he TB2 antigen-specific concentrations of the host markers (TB2
ntigen-minus-nil) were compared between the TB and ORD
roups, significant differences were obtained for the median levels
f seven markers. The levels of TGF- α were higher in the TB group
hereas those of p-selectin, EGF, IL-10, IL-13, MIP-1 α and GM-CSF
ere higher in the ORD group ( Table 4 ). EGF and p-selectin were
he most accurate TB2 antigen-specific individual biomarkers with
UCs of 0.66 (95%CI, 0.54–0.81) and 0.65 (95% CI, 0.52–0.78), re-
pectively, for the diagnosis of active TB. tility of combinations between different biomarkers in the diagnosis 
f TB 
When the data obtained from the unstimulated culture super-
atants were fitted to GDA models regardless of HIV infection sta-
us of study participants, a six-maker biosignature comprising of
po-A1, ITAC-1, I-309, MIG, MCP-2 and NCAM-1 diagnosed TB with
n AUC of 0.91 (95% CI, 0.88–0.97), corresponding to a sensitiv-
ty of 73.9% (95% CI, 51.6–89.8%) and specificity of 87.6% (95% CI,
7.2–94.5%). After leave-one-out cross-validation, the sensitivity of
he biosignature was 73.9% (95% CI, 51.6–89.8%) and specificity
as 86.2% (95% CI, 75.3–93.5%). The positive and negative predic-
ive values (PPV and NPV) of the biosignature (after leave-one-out
ross validation) were 68.0% (95% CI, 51.5–81.0%) and 90.5% (95%
I, 82.6–91.0%) respectively ( Fig. 2 (A)). When only the HIV unin-
ected participants were considered, a four-marker unstimulated
iosignature comprising of Apo-CIII, I-309, MIG and NCAM sim-
larly diagnosed TB disease with an AUC of 0.91 (95% CI, 0.85–
.98), corresponding to sensitivity of 82.4% (95% CI, 56.6–96.2%)
nd specificity of 87.3% (95% CI, 76.5–94.4%). The sensitivity and
pecificity of the biosignature were 76.5% (95% CI, 50.1–93.2%) and
5.7% (95% CI, 74.6–93.3%) respectively after leave-one-out cross
alidation, with PPV and NPV of 59.1% (95% CI, 42.8–73.4%) and
3.1% (95% CI, 85.0–96.8%), respectively ( Table 5 and, Fig. 2 (B)). 
When the TB1 antigen-specific marker data were similarly fitted
nto GDA models, regardless of HIV infection status, a four-marker
ignature comprising of Apo-CIII, I-309, MIP-1 α and TNF- α diag-
osed TB disease with an AUC of 0.72 (95% CI, 0.61–0.88), with
ensitivity and specificity of 62.9% (95% CI, 44.9–78.2%) and 73.3%
95% CI, 66.7–87.3%) respectively. After leave-one-out cross valida-
ion, the sensitivity and specificity of the biosignature were 54.3%
95% CI, 36.7–71.2%) and 72.5% (95% CI, 60.4–82.5%) respectively
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Table 4 
Median concentrations of host markers (Inter-quartile ranges in parenthesis) detected in TB2 antigen stimulated culture supernatants and accuracies in the diagnosis of TB 
disease. Only biomarkers that showed significant differences ( p ≤ 0.05) or trends (0.05 < 9 ≤ 0.1) between groups with the Mann Witney U test are shown. AUC = Area under 
the ROC curve, CI = Confidence interval. Cut-off values were selected based on the Youden’s Index. All concentrations are in pg/mL. 
Marker ORD( n = 69) (IQR) TB( n = 35) (IQR) P value ACU (95% CI) Cut-off value Sensitivity (95% CI) Specificity (95% CI) 
P-Selectin 0.1928 ( −0.402–0.7307) −0.2961 ( −1.35–0.2293) 0,0161 066 (0,54–0.81) 0.03092 76 (53–92) 60 (47–72) 
EGF 0,6551 ( −0.4189–0.5737) 0.2845 (0.7855–0.0088) 0.0333 0.65 (0.52–0.78) −0.01726 77 (55–92) 62 (49–73) 
GM-CSF 0.1559 ( −0.3593–0.6323) −0.1459 ( −0.6546–0.1884) 0.0327 0.63 (0.51–0.75) −0.1396 66 (48–81) 65 (53–75) 
IL-10 0.1892 ( −0.5080–0.6323) −0.5043 (0.8695–0.5049) 0.0384 0.63 (0.51–0.74) 0.09878 73 (54–88) 61 (48–72) 
IL-13 −0.2060 −0.4324–0.7489) −0.3809 ( −0.7489–0.2386) 0.0860 0,61 (0.41–0.72) −0.2277 64 (40–85) 54 (41–66) 
MIP-1 α −0.1482 ( −0.389–0.3574) −0.294 (0.6531–09609) 0.0914 0.60 (0,49–0,72) −0.1986 70 (48–82) 55 (43–67) 
TGF- α 0.086 ( −0,8910–0.3405) 0.152 ( −0.5266–0.9270) 0,02068 0.56 (0.45–0.70) −0.08228 60 (38–63) 51 (38–63) 
Values shown were background corrected by subtraction of the unstimulated from the antigen-stimulated concentration for each study participant. A negative value before 
a number indicates that the unstimulated concentrations of the biomarker were higher than the TB2 antigen-stimulated values. 
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Fig. 2. Usefulness of combinations of host markers detected in QFT Plus supernatants in diagnosis of TB disease. ROC curves showing the accuracies of the different biosigna- 
tures described in the text and Table 5 . A, ROC curve showing the accuracy of biosignature (i): combinations between unstimulated host markers regardless of HIV infection. 
B, ROC curve showing the accuracy of biosignature (ii): combinations between unstimulated markers in HIV uninfected individuals. C, ROC curve showing the accuracy of 
biosignature (iii): combinations between TB1 antigen-specific host markers regardless of HIV infection. D, ROC curve showing the accuracy of biosignature (iv): combinations 
between TB2 antigen-specific host markers regardless of HIV infection. E, ROC curve showing the accuracy of biosignature (v): combinations between TB1&TB2 antigen- 
specific host markers regardless of HIV infection. F, ROC curve showing the accuracy of biosignature (vi): combinations between TB1&TB2 antigen-specific host markers in 




















c  ( Table 5 and Fig. 2 (C)). When TB-2 antigen-specific data were fit-
ted into GDA models, again regardless of HIV infection status, a
four-maker biosignature comprising of IL-6, MIP-1 α, GM-CSF and
TGF- α diagnosed TB disease with an AUC of 0.72 (95% CI, 0.60–
0.84), corresponding to a sensitivity 60.0% (95% CI, 42.0–76.1%) and
specificity of 79.1% (95% CI, 68.3–88.4%). After leave-one-out cross
validation, the sensitivity of the biosignature was 57.1% (95% CI,
65.1–86.1%) and the specificity was 71.6% (95% CI, 39.4–73.7%)
( Table 5 and Fig. 2 (D)). 
When we evaluated combinations between TB1 and TB2 antigen-
specific biomarkers , again, regardless of HIV infection status, a four-
marker biosignature comprising of TNF- α, LIGHT, MIG, and p-
selectin diagnosed TB disease with a sensitivity of 77.3% (95% CI, n4.6–92.2%) and specificity of 72.3% (95% CI, 59.8–82.7%). After
eave-one-out cross validation, the sensitivity and specificity of the
iosignature were 77.3% (95% CI, 54.5–92.2%) and 69.2% (95% CI,
6.6–80.1%), respectively ( Table 5 , Fig. 2 (E) and (F)). 
ifferential expression of host biomarkers in TB patients and 
uantiferon Plus positive vs. Quantiferon Plus negative individuals 
ith ORD 
We evaluated the ability of the different host markers in dis-
riminating between TB patients, QFT Plus positive, and QFT Plus
egative patients with ORD. 
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Table 5 
Summary of biosignatures identified in the current study. AUC = Area under the ROC curve, Spec = Specificity, Sens = Sensitivity, PPV = Positive predictive values, NPV = 
Negative predictive value. 
Biosignature AUC (95% CI) 
Classification matrix Leave-one-out cross validation 
Sens (%) Spec (%) Sens (%) Spec (%) PPV (%) NPV (%) 
Biosignature (i): Markers detected in unstimulated (nil) supernatants, regardless of HIV infection 
APO –CII + CXCL1/ITAC- 
1 + CXCL9/MIG + CCL8/MCP-2 + I- 















Biosignature (ii): Markers detected in unstimulated (nil) supernatants, only in HIV uninfected participants 
CXCL9/MIG + CCL1/I- 
















Biosignature (iii): TB1 antigen-specific biomarkers (TB1 Ag-minus nil), regardless of HIV infection status 
CFH + CCL1/I-309 + CCL4/MIP- 















Biosignature (iv): TB2 antigen-specific biomarkers (TB2 Ag-minus nil), regardless of HIV infection status 
IL-6 + CCL4/MIP-1 α+ GM- 















Biosignature (v): Combinations between TB1 and TB2 antigen-specific biomarkers, regardless of HIV infection status 















Biosignature (vi): Combinations between TB1 and TB2 antigen-specific biomarkers, only in HIV uninfected patients 
ADAMTS13 + CCL1/I- 




























































































i  Using the Mann Whitney U test, 16 of the proteins detected in
nstimulated supernatants including I-309, ITAC-1, IL-3, IL-33, MIG
nd Apo-CIII (see Supplementary Table 1 ) were significantly dif-
erent between individuals with TB disease and QFT Plus positive
ndividuals with ORD. Apo-A1, MIG, Apo-CIII, ITAC-1 and IL-1 α lev-
ls were significantly different between TB patients and QFT Plus
egative individuals with ORD whereas, none of the 37 biomark-
rs detected in unstimulated supernatants showed differences be-
ween QFT Plus positive and QFT Plus negative individuals with
RD (Supplementary Table 1 ). 
When the TB1 antigen specific (TB1Ag-nil) host markers were
ompared between the three groups, 14 proteins including IL-
3, MIP-1 α, IL-3, GM-CSF, IL-1 α and IL-10 (see Supplementary
able 2 ) were significantly different between the TB patients and
FT plus positive individuals with ORD. Surprisingly, only IP-10
nd p-selectin were significantly different between patients with
ctive TB and QFT Plus negative individuals with ORD, whereas
FN- ү, IL-13, IL-2, MCP-2, and ITAC-1 antigen-specific levels were
ignificantly different between QFT Plus positive and QFT Plus neg-
tive individuals with ORD (Supplementary Table 2 ). 
When the TB2 antigen-specific host markers (TB2 Ag-nil) were
ompared between groups, nine proteins including IL-6, IL-13, GM-
SF, IL-10, IL-2, and MIP-1 α showed significant differences be-
ween TB patients and QFT Plus positive individuals with ORD.
hen the TB patients were compared to QFT Plus negative individ-
als with ORD, only IFN- γ and p-selectin levels were significantly
ifferent, whereas TB2 antigen-specific IFN- ү, MIP-1 α, IL-22, IL-13,
nd GM-CSF were significantly different between QFT Plus posi-
ive and QFT Plus negative individuals with ORD (Supplementary
able 3 ). 
iscussion 
In the current study, we evaluated the usefulness of host mark-
rs that showed potential in previous studies including antigen-
timulated (mainly QFT In tube) culture supernatants as well as
erum and plasma specimens, as diagnostic candidates for TB
isease. As the QFT Plus test is reportedly more sensitive and
pecific for M. tb infection than the QFT In Tube; the previous
eneration of the test, 18 we hypothesized that host biomarkershat previously showed potential, especially in QFT In tube super-
atants will perform with improved accuracy. Many individual host
iomarkers that are detectable in either unstimulated, TB1 or TB2
ntigen-stimulated supernatants including ITAC-1, IL-3, I-309, MIG,
po-A1, p-selectin, MIP-1 α, EGF, GM-CSF, IL-2 and IL-10 showed
otential in the diagnosis of TB disease in this study. However, as
bserved in previous studies (14, 29, 36), combinations between
ifferent biomarkers were more accurate than individual analytes,
ith combinations of analytes detected in the unstimulated super-
atants being the most accurate in the diagnosis of TB disease. 
Out of the 14 host markers that showed potential in diagnos-
ng TB disease in unstimulated supernatants, four, namely, ITAC-1,
L-3, I-309 and MIG were amongst the most promising analytes
dentified in plasma in a previous study. 25 Other host biomark-
rs which showed potential including EGF, TGF- α, IL-2, IL-33,
po-A1, ADAMTS13, GM-CSF and IP-10 also showed potential in
revious studies. 3,15 , 28–33 Our findings from unstimulated culture
upernatants are therefore in agreement with these previous stud-
es, and indicate that these proteins may be strong candidate
iomarkers for the diagnosis of active TB. 
It is widely known that CD4 T cells play an important role in
he immune response against M. tb infection through production
f IFN- γ and other host markers. However, in addition to CD4 T
ells, evidence from previous studies have shown that CD8 T cells
lso play an important role during M. tb infection through pro-
uction of cytokines. 18,34,35 The addition of CD8 + T -cell stimulat-
ng peptides into one of the QFT Plus tubes is hypothesised to
ave increased the sensitivity for diagnosing M. tb infection as well
s active TB. 18,36 In this study however, the most promising host
arkers for the diagnosis of active TB were detected in unstimu-
ated supernatants and not supernatants from the antigen contain-
ng tubes. Antigen-specific biomarkers that showed potential after
timulation with the TB2 antigens included IL-13, TGF- α, MIP-1 α,
GF, GM-CSF, IL-10 and p-selectin. 
IL-13 is a cytokine that is secreted by many cell types in-
luding CD4 T cells, natural killer cells, esosinophils amongst
thers and is mostly associated with T helper 2 immu-
ity. 37 MIP-1 α is a chemoattractant that is mainly produced by
acrophages after stimulation with bacterial endotoxins. IL-10
s an anti-inflammatory cytokine which inhibits the synthesis of






















































































































pro-inflammatory cytokines includ IFN- γ , TNF- α and IL-2 which
are mainly produced by T cells and macrophages. 38 GM-CSF is a
glycoprotein which functions as a cytokine and is produced by
various immune cells including T cells, natural killer cells and
macrophages. Its role is to stimulate stem cells which produce
granulocytes and monocytes 39 whereas p-selectin is a cell adhe-
sion molecule which is found on the surface of the endothelial
cells. 40 EGF and TGF- α are growth factors. EGF stimulates cell
growth and differentiation amongst other functions and enhances
the growth of extracellular and intracellular M. tb at the site of
infection. 41 TGF- α plays an important role as an EGF receptor lig-
and, which activates the signalling pathway for proliferation, acti-
vation and development of the cell. Upregulation of these growth
factors in QFT supernatants from TB patients was demonstrated in
previous studies. 3 We only observed the findings for the growth
factors in the TB2 and not TB1 culture supernatants. It is not clear
whether CD4 or CD8 T cells were the main producers of these pro-
teins. If only CD8 T Cells, then it does not explain the observation
of these proteins in previous QFT In Tube based studies (14, 27)
and requires further investigation. QFT Plus is meant for the di-
agnosis of M. tb infection. We observed differences in the expres-
sion of some of the biomarkers evaluated between patients with
active TB, QFT Plus positive patients with ORD and QFT Plus nega-
tive patients with ORD as shown in the supplementary files. How-
ever, we did not perform extensive analysis for these differences
as this was not the main focus of the current study. Our goal was
to evaluate the performance of biomarkers in diagnosing active TB,
regardless of whether individuals presenting with symptoms were
latently infected or not, as this study was conducted in a high
burden setting. As observed in previous studies, combinations be-
tween multiple host biomarkers performed better in the diagnosis
of TB disease, 26,42,43 with a different optimal, and smaller biosig-
nature obtained if only HIV uninfected participants were consid-
ered. We were not sufficiently powered to perform a detailed anal-
ysis of the influence of HIV infection on the biomarkers as only
14 of the study participants, and only two out of the 69 individ-
uals in whom TB was ruled out (3% of the ORD group) and 7 out
of the 35 TB patients (20%) were infected with HIV. Combinations
between antigen-specific biomarkers were inferior to the perfor-
mance of biomarkers obtained in unstimulated supernatants and
for optimal diagnosis using antigen-specific biomarkers, our data is
in favour of combinations between both the TB1 and TB2 antigen-
specific markers. 
Given the recent findings that biomarkers detectable in serum,
plasma, urine and saliva samples may be useful, and even per-
formed better than the accuracy obtained in QFT Plus supernatants
in the current study, 12,23,29,40 the utility of QFT Plus-based host
biomarkers might be limited. The use of such antigen-specific
host markers may be important in specific niche groups in the
difficult-to-diagnose TB including childhood and extrapulmonary
TB. 44 More research is needed to ascertain the position of such
biomarkers in the TB diagnostic landscape. 
The strengths of the current study include the prospective,
phase III design and the fact that it was conducted in an area with
one of the highest TB burdens in the world, with a high prevalence
of LTBI 1 and our findings may be relevant regarding field applica-
bility of the. However, our sample size was relatively small, owing
to costs. Future studies should evaluate the most promising ana-
lytes identified in the present study in samples obtained from mul-
tiple sites. The severity of HIV infection in any infected participants
should be determined, and used to assess the possible influence of
HIV on the accuracy of the biomarkers. Such studies may include
children and patients with extrapulmonary TB. 
In conclusion, our findings indicate that some of the host mark-
ers identified as TB diagnostic candidates in previous studies show
potential as diagnostic candidates for TB disease, when measuredn QFT Plus supernatants. Biosignatures obtained from unstim-
lated culture supernatants were more promising than antigen-
timulated biomarkers, indicating that ex vivo blood, serum or
lasma based assays may be preferable to antigen-stimulated as-
ays. Our findings require validation in other, larger studies. 
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